Research programme: insulin resistance therapies - Pfizer/Sanford-Burnham Medical Research Institute
Latest Information Update: 15 Aug 2013
At a glance
- Originator Pfizer; Sanford-Burnham Medical Research Institute
- Developer Pfizer; Sanford Burnham Prebys Medical Discovery Institute
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Insulin resistance
Most Recent Events
- 13 Aug 2013 Early research in Insulin resistance (in obesity and diabetes) in USA (unspecified route)